{"organizations": ["Vivus"], "uuid": "d3f976fbb6f3184e13b2153ddbb60bc22a764481", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "finance.yahoo.com", "main_image": "http://l3.yimg.com/bt/api/res/1.2/M7vS95b2fvSzHFeFStPk0A--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "http://finance.yahoo.com/rss/headline?s=VVUS", "section_title": "Yahoo! Finance: VVUS News", "url": "http://finance.yahoo.com/news/icahn-offer-considered-critical-information-124000491.html", "country": "GB", "title": "Icahn Offer Considered - Critical Information for Vivus Shareholders", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "Icahn Offer Considered - Critical Information for Vivus Shareholders", "spam_score": 0.0, "site_type": "news", "published": "2015-09-10T15:40:00.000+03:00", "replies_count": 0, "uuid": "d3f976fbb6f3184e13b2153ddbb60bc22a764481"}, "author": "", "url": "http://finance.yahoo.com/news/icahn-offer-considered-critical-information-124000491.html", "ord_in_thread": 0, "title": "Icahn Offer Considered - Critical Information for Vivus Shareholders", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": ["Icahn"], "text": "Content preferences Done \nNEW YORK, NY / ACCESSWIRE / September 10, 2015 / Vivus, Inc., ( VVUS ) whose shares shot up immediately at the market opening yesterday morning, to a daily high of $1.66, representing a 38% increase from the previous close of $1.20, settled back down to close for the day at $1.35. Still, a significant gain for an issue that has been battered and beaten down since 2012. Volume ratcheted up to nearly 13 million shares, against an average daily volume of less than 2 million. Vivus has gained more than 15% during the last five trading days, and is up over 17% for the past thirty trading days. \nThe bio-pharmaceutical firm is involved in the treatment of obesity and erectile dysfunction, with two sponsored, FDA approved drugs on the market: Qsymia (weight control) and STENDRA (sexual health). \nIcahn Enterprises subsidiary IEH Biopharma, LLC, has made a cash tender offer for all of VVUS outstanding Convertible Senior Notes, due 2020, at a price of $680 per $1,000 of principal amount, plus interest. The offer expires at 5:00pm EST 7 October 2015. Vivus, based in Mountain View, California, had no comment on the offer. Likewise, IEH offered neither specific follow-up comments nor a platform of reasoning behind the offer. \nIn after hours trading, VVUS closed the session seven cents higher, to $1.42 per share for an additional gain of 5.2%. \nFor more insight into what the future of VVUS may hold use the link below for due diligence report. \nCopy and paste may be required. \nAbout Broad Street Alerts \nWe make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. \nSafe Harbor Statement \nThis press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements. \nCompliance Procedure \nContent is researched, written and reviewed on a best-effort basis by a 3 rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below.", "external_links": [], "published": "2015-09-10T15:40:00.000+03:00", "crawled": "2015-09-10T18:03:05.351+03:00", "highlightTitle": ""}